| 1371 |
National Cancer Institute |
Html |
en |
Testicular Cancer Screening (PDQ®)–Health Professional Version |
For testicular cancer, there is no standard or routine screening test. Review the limited evidence on the benefits and harms of screening for testicular cancer using ultrasound, physical examination, and self-examination in this expert-reviewed summary. |
| positive predictive value | 0.695776 |
| routine screening | 0.564923 |
| metastatic potential | 0.563198 |
| Anaplastic seminoma accounts | 0.622576 |
| different geographical areas | 0.620061 |
| physical examination | 0.605096 |
| clinical testicular examination | 0.721514 |
| Caucasian populations. | 0.566499 |
| testicular cancer | 0.951907 |
| postnatal risk factor | 0.601402 |
| white men | 0.624527 |
| ethnic groups | 0.563052 |
| testicular cancers | 0.797374 |
| previously impalpable gonad | 0.603117 |
| effective treatments | 0.565355 |
| intermediate incidence rates | 0.604976 |
| American population. | 0.564647 |
| annual increase | 0.563525 |
| dramatic decrease | 0.576242 |
| observed incidence | 0.56787 |
| new cases | 0.568142 |
| appreciable change | 0.564646 |
| testicular self-examination | 0.687127 |
| genetic risk factors | 0.600847 |
|
| single-center case series | 0.602561 |
| U.S. Preventive Services | 0.59719 |
| United States | 0.618395 |
| testicular tumors | 0.686049 |
| pure seminomas | 0.561939 |
| testicular symptoms | 0.684314 |
| common cancer | 0.580765 |
| common malignancy | 0.57065 |
| quasi-randomized controlled trials | 0.594715 |
| Cochrane Collaboration review | 0.593748 |
| asymptomatic population. | 0.565357 |
| routine physical examination | 0.599315 |
| black men | 0.575106 |
| Classic seminoma accounts | 0.61307 |
| Testicular Cancer Treatment | 0.746488 |
| United Kingdom | 0.56682 |
| young men | 0.581551 |
| higher rate | 0.65969 |
| human chorionic gonadotropin | 0.610455 |
| asymptomatic men | 0.627381 |
| testicular ultrasound. | 0.684097 |
| mortality | 0.565405 |
| greater mitotic activity | 0.608461 |
| screening setting | 0.564489 |
|
CLICK HERE |
| 1425 |
National Cancer Institute |
Html |
en |
Ewing Sarcoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of Ewing sarcoma. |
| ewing sarcoma | 0.955451 |
| Localized Ewing Sarcoma | 0.516622 |
| standard-risk Ewing sarcoma | 0.50921 |
| localized ewing tumors | 0.458678 |
| pelvic ewing sarcoma | 0.53548 |
| non-metastatic ewing | 0.447666 |
| Ewing family tumors | 0.476484 |
| Cooperative Ewing Sarcoma | 0.57252 |
| Primary Ewing tumor | 0.442949 |
| genetically confirmed Ewing | 0.443739 |
| recurrent Ewing sarcoma | 0.50281 |
| high-risk Ewing sarcoma | 0.510965 |
| soft tissue ewing | 0.474262 |
| Ewing sarcoma regimen | 0.517079 |
| Sarcoma Studies patients | 0.436849 |
| sarcoma treatment | 0.437736 |
| ewing sarcoma family | 0.677203 |
| Ewing sarcoma patients | 0.582131 |
| Ewing tumor patients | 0.46609 |
| Ewing Sarcoma Study | 0.512708 |
| radiation therapy | 0.475396 |
| Cutaneous Ewing sarcoma | 0.543452 |
| Ewing sarcoma trials | 0.520061 |
| extraosseous Ewing sarcoma. | 0.438839 |
| et al. | 0.575718 |
|
| extraskeletal Ewing sarcoma | 0.55299 |
| tissue Ewing sarcoma | 0.517715 |
| sarcoma family tumors | 0.500986 |
| Ewing sarcoma molecularly. | 0.525686 |
| nonmetastatic Ewing sarcoma | 0.582468 |
| secondary Ewing sarcoma | 0.532715 |
| PUBMED Abstract | 0.436153 |
| extraosseus Ewing tumors | 0.450361 |
| extraosseous ewing sarcoma | 0.608612 |
| Pediatr Blood Cancer | 0.643087 |
| prognosis Ewing family | 0.435199 |
| Intergroup Cooperative Ewing | 0.452427 |
| advanced Ewing tumors | 0.44875 |
| nonmetastatic extraosseous Ewing | 0.439621 |
| subcutaneous Ewing sarcoma | 0.543232 |
| Ewing sarcoma. | 0.468942 |
| primary Ewing sarcoma | 0.527784 |
| Abstract | 0.588175 |
| Clin Oncol | 0.669349 |
| multifocal Ewing sarcoma | 0.559473 |
| metastatic Ewing tumors | 0.450872 |
| Ewing tumor | 0.52176 |
| ewing tumors | 0.573464 |
| non metastatic Ewing | 0.435213 |
|
CLICK HERE |
| 1563 |
National Cancer Institute |
Html |
en |
Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of intraocular (uveal) melanoma. |
| intraocular melanoma spreads | 0.250336 |
| intraocular melanoma | 0.910343 |
| millimeters | 0.391159 |
| metastatic intraocular melanoma | 0.214724 |
| PDQ cancer information | 0.259005 |
| choroid | 0.268515 |
| clinical trial search | 0.285225 |
| cancer information summary | 0.225998 |
| clinical trial | 0.443006 |
| iris | 0.239636 |
| Gamma Knife therapy | 0.228475 |
| patients | 0.209232 |
| blood vessels | 0.304976 |
| intraocular melanoma tumors | 0.226899 |
| eye | 0.424632 |
| radiation therapy | 0.510988 |
| malignant tumor cells | 0.271535 |
| optic nerve | 0.24596 |
| eyeball | 0.243675 |
| intraocular melanoma forms | 0.241987 |
| small choroid melanoma | 0.211146 |
| treatment | 0.429108 |
| Charged-particle external-beam radiation | 0.231587 |
| intraocular melanoma cells | 0.228349 |
| recurrent intraocular melanoma | 0.212624 |
|
| choroid melanoma | 0.222278 |
| NCI-supported cancer | 0.212728 |
| cancer cells | 0.209946 |
| plaque radiation therapy | 0.308242 |
| small tumor | 0.233192 |
| common eye cancer | 0.210231 |
| treatment clinical trials | 0.228682 |
| National Cancer Institute | 0.24241 |
| new treatment | 0.231582 |
| external-beam radiation therapy | 0.278674 |
| clinical trials | 0.677613 |
| primary tumor | 0.231468 |
| ciliary body | 0.781488 |
| metastatic tumor | 0.244372 |
| medium choroid melanoma | 0.210302 |
| large choroid melanoma | 0.209378 |
| cancer clinical trials | 0.291937 |
| stage | 0.237259 |
| tumor | 0.76237 |
| high-energy sound waves | 0.239767 |
| treatment options | 0.227265 |
| internal radiation therapy | 0.245892 |
| cancer | 0.592755 |
| information | 0.28047 |
|
CLICK HERE |
| 1731 |
National Cancer Institute |
Html |
en |
Oral Contraceptives and Cancer Risk |
A fact sheet about research on the association of oral contraceptive use (birth control pills) with risk of various cancers. |
| oral contraceptives | 0.917263 |
| hereditary ovarian cancer | 0.383854 |
| commonly prescribed type | 0.33973 |
| liver cancer risk | 0.373941 |
| estrogen-progestogen contraceptives | 0.386723 |
| benign liver tumors | 0.371652 |
| risk level | 0.342841 |
| increased risk | 0.351993 |
| time oral contraceptives | 0.52153 |
| ovarian cancer | 0.597198 |
| cervical cancers | 0.357191 |
| birth control pills | 0.477503 |
| cervical cancer | 0.513015 |
| female hormones | 0.362642 |
| hormonal factors | 0.355222 |
| widely used contraceptives | 0.420798 |
| slightly higher risk | 0.352236 |
| oral contraceptive formulations | 0.41375 |
| human papillomavirus | 0.360793 |
| endometrial cancer | 0.391533 |
| Cancer Epidemiology Biomarkers | 0.379203 |
| Cancer Clinical Study | 0.356619 |
| women | 0.413442 |
| study | 0.369792 |
| United States | 0.339309 |
|
| low progestin levels | 0.339553 |
| endometrial cancer risk | 0.376136 |
| oral contraceptive contains | 0.427683 |
| oral contraception | 0.377158 |
| breast cancers | 0.339078 |
| National Cancer Institute | 0.35154 |
| oral contraceptive. | 0.39193 |
| epithelial ovarian cancer | 0.36885 |
| female hormones estrogen | 0.346135 |
| ovarian cancer risk | 0.5032 |
| epidemiological studies | 0.347746 |
| cervical cancer risk | 0.402371 |
| higher risk | 0.352753 |
| hormonal contraceptives | 0.40794 |
| breast cancer risk | 0.408785 |
| protective effect increases | 0.369195 |
| Abstract | 0.338219 |
| breast cancer | 0.500449 |
| malignant liver tumors | 0.371449 |
| birth control pill | 0.342382 |
| cancer risk | 0.531533 |
| et al | 0.421561 |
| New England Journal | 0.388183 |
| cancer | 0.613253 |
|
CLICK HERE |
| 1784 |
National Cancer Institute |
Html |
es |
Complicaciones orales de la quimioterapia y la radioterapia a la cabeza y el cuello (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las complicaciones orales, como la mucositis y la disfunción de la glándula salival, que se presentan en pacientes de cáncer tratados con quimioterapia y radioterapia a la cabeza y el cuello. |
| Cancer Inst Monogr | 0.239559 |
| Schubert MM | 0.377541 |
| cuidado dental | 0.263915 |
| Oral complications | 0.73133 |
| oral involvement | 0.311957 |
| Hong CH | 0.250225 |
| Stem Cell Transplantation | 0.260042 |
| tóxicos orales agudos | 0.296836 |
| infecciones vÃricas tardÃas | 0.240097 |
| mucosa inmunidad | 0.238568 |
| oral cryotherapy | 0.302117 |
| Oral Care Study | 0.325881 |
| efectos tóxicos directos | 0.264484 |
| oral básica | 0.298176 |
| cell transplantation | 0.36439 |
| Epstein JB | 0.250634 |
| hematopoietic cell transplantation | 0.356137 |
| Oral Dis | 0.304725 |
| Oral Oncology | 0.315424 |
| patients treated with | 0.256291 |
| oral sistemática | 0.403576 |
| Pretreatment oral assessment | 0.299848 |
| cáncer causa efectos | 0.235719 |
| células madre | 0.562689 |
| oncologÃa oral | 0.303702 |
|
| Cancer Quality | 0.23962 |
| Care Cancer | 0.911761 |
| Brennan MT | 0.291094 |
| Oral biofilms | 0.300769 |
| Johnson BS | 0.249495 |
| recuperación hematopoyética infecciones | 0.23764 |
| Oral Oncol | 0.388386 |
| EICH oral aguda | 0.30451 |
| quimioterapia mielosupresora | 0.237026 |
| Dowd FJ | 0.255583 |
| Pathol Oral Radiol | 0.29984 |
| Complicaciones Citas | 0.24913 |
| patients receiving | 0.238033 |
| Sonis ST | 0.246364 |
| Peterson DE | 0.312811 |
| Mosby Elsevier | 0.254331 |
| Surg Oral Med | 0.300003 |
| systematic review | 0.853357 |
| 6th ed | 0.252103 |
| dental extractions | 0.245651 |
| Yagiela JA | 0.254334 |
| Oral Maxillofac Surg | 0.292509 |
| cuidado oral | 0.503096 |
| oral citotoxicidad | 0.308917 |
|
CLICK HERE |
| 1868 |
National Cancer Institute |
Html |
es |
Tratamiento del linfoma de Hodgkin infantil (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del linfoma de Hodgkin infantil. |
| lymphocyte predominant hodgkin | 0.379318 |
| Cancer Statistics Review | 0.310924 |
| patients with hodgkin | 0.340461 |
| Epstein-Barr virus with | 0.308343 |
| lymphocyte predominance hodgkin | 0.361894 |
| Pediatric Lymphocyte-Predominant Hodgkin | 0.335497 |
| with nodular lymphocyte | 0.31309 |
| Epstein-Barr virus | 0.324897 |
| localized childhood hodgkin | 0.334572 |
| familial classical hodgkin | 0.33579 |
| células reed-sternberg | 0.313182 |
| Radiat Oncol Biol | 0.310379 |
| oncology group study | 0.317944 |
| adolescent hodgkin | 0.33572 |
| Children's Oncology Group | 0.329911 |
| Estados Unidos | 0.310464 |
| siguientes caracterÃsticas | 0.32336 |
| Leuk Lymphoma | 0.318529 |
| hodgkin's lymphoma | 0.723879 |
| childhood hodgkin | 0.361352 |
| SEER Cancer Statistics | 0.312001 |
| classic hodgkin | 0.335243 |
| pediatric hodgkin | 0.427701 |
| IV Hodgkin | 0.334995 |
| adultos jóvenes | 0.32544 |
|
| estadio iv | 0.319107 |
| nodular lymphocyte-predominant hodgkin | 0.387944 |
| nodular sclerosing hodgkin | 0.337374 |
| high-risk hodgkin | 0.334348 |
| pediatric patients with | 0.317448 |
| with hodgkin | 0.425646 |
| linfadenopatÃa periférica | 0.308361 |
| non-Hodgkin's lymphoma | 0.3114 |
| advanced hodgkin | 0.335086 |
| National Cancer Institute | 0.316464 |
| report from | 0.308961 |
| with classical hodgkin | 0.37144 |
| Hodgkin's lymphoma after | 0.346052 |
| Epstein-Barr virus infection | 0.309022 |
| células reed-sternberg llamadas | 0.308458 |
| Pediatr Hematol Oncol | 0.310971 |
| Lymphoma project | 0.310216 |
| Clin Oncol | 0.390721 |
| Hodgkin Lymphoma Group | 0.341816 |
| Oncol Biol Phys | 0.310469 |
| hodgkin lymphoma | 0.986519 |
| lymphocyte-predominant hodgkin lymphoma | 0.45063 |
| Cancer Institute | 0.316934 |
| classical hodgkin lymphoma | 0.529436 |
|
CLICK HERE |
| 1880 |
National Cancer Institute |
Html |
es |
Tratamiento del osteosarcoma e histiocitoma fibroso maligno óseo (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del osteosarcoma/histiocitoma fibroso maligno óseo. |
| extraosseous osteosarcoma | 0.278507 |
| Cancer Res Clin | 0.254374 |
| neoadjuvant cooperative osteosarcoma | 0.358725 |
| Orthop Relat Res | 0.284141 |
| cooperative osteosarcoma study | 0.829513 |
| german-austrian-swiss osteosarcoma study | 0.35683 |
| treated with neoadjuvant | 0.233828 |
| osteosarcoma after | 0.343245 |
| german cooperative osteosarcoma | 0.359475 |
| Cancer Res | 0.262493 |
| Radiat Oncol Biol | 0.22414 |
| Delling G | 0.216109 |
| prognostic factor | 0.261147 |
| Ferrari S | 0.223793 |
| Res Clin Oncol | 0.245253 |
| Bone Joint Surg | 0.218249 |
| Children's Oncology Group | 0.273207 |
| Natl Cancer Inst | 0.230083 |
| osteogenic sarcoma | 0.27919 |
| osteosarcoma study | 0.934201 |
| neoadjuvant chemotherapy | 0.393798 |
| patients with | 0.508039 |
| patients with sarcoma | 0.221174 |
| to neoadjuvant chemotherapy | 0.216616 |
| adult patients with | 0.217534 |
|
| with neoadjuvant chemotherapy | 0.275342 |
| Longhi A | 0.235836 |
| bone tumors | 0.220948 |
| osteosarcoma after treatment | 0.281068 |
| Skin Cancer | 0.215986 |
| Pediatr Blood Cancer | 0.257287 |
| extremities treated with | 0.216311 |
| osteosarcoma study group | 0.718583 |
| study group protocols | 0.222417 |
| report from | 0.244375 |
| Nucl Med | 0.231164 |
| with poor prognosis | 0.215443 |
| Surg Oncol | 0.266751 |
| with adjuvant chemotherapy | 0.223288 |
| Osteosarcoma over | 0.282528 |
| extremity treated with | 0.216299 |
| Pediatr Hematol Oncol | 0.285762 |
| Clin Oncol | 0.832414 |
| operable osteosarcoma | 0.283119 |
| patients treated | 0.236043 |
| cooperative german-austrian-swiss osteosarcoma | 0.35251 |
| Oncol Biol Phys | 0.224271 |
| Bacci G | 0.350792 |
| Oncology Group | 0.276126 |
|
CLICK HERE |
| 2010 |
National Cancer Institute |
Html |
es |
Grados de comprobación científica de los estudios de investigación sobre detección y prevención del cáncer (PDQ®)–Versión para profesionales de salud |
Información acerca de cómo evaluar la solidez de los datos probatorios obtenidos en los estudios de investigación sobre detección y prevención del cáncer. |
| Woolf SH | 0.300601 |
| Helfand M | 0.300564 |
| sección datos | 0.302661 |
| Current methods | 0.300631 |
| importancia clÃnica | 0.300524 |
| Consejo editorial usa | 0.301821 |
| datos probatorios indirectos | 0.302664 |
| Prev Med | 0.300645 |
| beneficios opción | 0.300848 |
| National Cancer Institute | 0.300824 |
| medida estudios | 0.300552 |
| Preventive Services Task | 0.303591 |
| Instituto Nacional | 0.30261 |
|
| Visuals Online | 0.300487 |
| intervenciones invasoras | 0.300666 |
| Harris RP | 0.300578 |
| Physician Data Query | 0.300891 |
| Services Task Force | 0.303562 |
| datos probatoriosUn estudio | 0.301838 |
| posibles beneficios | 0.30077 |
| datos probatorios | 0.994126 |
| acuerdo vs | 0.301691 |
| participantes vs | 0.301672 |
| US Preventive Services | 0.301 |
| perjuicios opción | 0.301319 |
| mejores estudios | 0.300602 |
|
CLICK HERE |
| 2956 |
National Cancer Institute |
Html |
en |
Stress and Smoking |
Many people smoke when they feel stressed. A major part of quitting smoking is finding ways to handle your stress. Get tips on ways you can reduce stress in your life. |
| mood | 0.321745 |
| yoga | 0.311766 |
| smokers | 0.257588 |
| effective—like | 0.254092 |
| body | 0.252396 |
| short walk | 0.459288 |
| lowers | 0.345038 |
| ways | 0.478317 |
| problem | 0.256426 |
| solution | 0.253633 |
| smoking | 0.723433 |
| things | 0.251219 |
| nicotine feel | 0.464166 |
| healthy ways | 0.416006 |
| oxygen | 0.318701 |
| quitting | 0.25513 |
|
| unpleasant feelings | 0.498181 |
| stress | 0.995674 |
| relaxation exercise | 0.463458 |
| cigarette | 0.258889 |
| emotions | 0.253066 |
| withdrawal | 0.2602 |
| Nicotine addiction | 0.459283 |
| brain | 0.303202 |
| people | 0.263655 |
| long-term stress reliever | 0.883552 |
| calms nerves | 0.742794 |
| cigarettes | 0.42465 |
| depression | 0.30341 |
| time | 0.25441 |
| better ways | 0.410713 |
| Cravings | 0.267404 |
|
CLICK HERE |
| 3932 |
National Cancer Institute |
Html |
es |
Aprenda a relajarse |
Ejercicios de relajación y de visualización para ayudar a reducir el dolor y el estrés del cáncer y de su tratamiento. |
| pequeña almohada | 0.868399 |
|
| agradable sensación | 0.763417 |
|
CLICK HERE |